Újpesti Egészségügyi Nonprofit Kft
Welcome,         Profile    Billing    Logout  
 7 Trials 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kautzky-Willer, Alexandra
Test2Func, NCT03851627: Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Recruiting
4
32
Europe
Testosterone Undecanoate, Nebido, Placebo, oily solution, Nebido like Placebo
Alexandra Kautzky-Willer, Bayer
Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male
09/28
12/28
NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Recruiting
4
2400
Europe, RoW
RAS-antagonist and beta-blocker up-to maximal dosages, Enalapril 40mg/d, Ramipril 10mg/d, Lisinopril 40mg/d, Cilazapril 5mg/d, Perindopril 8mg/d, Captopril 150mg/d, Spirapril 24mg/d, Quinapril 40mg/d, Trandolapril 4mg/d, Zofenopril 60mg/d, Fosinopril 40mg/d, Candesartan 32mg/d, Valsartan 320mg/d, Irbesartan 300mg/d, Losartan 150mg/d, Eprosartan 800mg/d, Bisoprolol 10mg/d, Metoprololsuccinat 200mg/d, Carvedilol 50mg/d (100mg/d if weight is > 85kg), Nebivolol 10mg/d, RAS-antagonist and beta-blocker none or at stable dose
Martin Huelsmann
Heart Diseases, Diabetes Mellitus, Type 2
12/25
12/26
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06245681: Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content

Recruiting
N/A
40
Europe
gender affirming hormone therapy
Medical University of Vienna
Gender Dysphoria
10/25
10/25
NCT06291675: Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content

Recruiting
N/A
50
Europe
gender-affirming hormone therapy
Medical University of Vienna
Gender Dysphoria, Hormone Therapy Induced Morphologic Change
03/26
03/33
DiabesityDay, NCT06680674: Multinational Point Prevalence Study on the Management of Diabesity in Hospitals

Not yet recruiting
N/A
400
NA
Routine care for people with diabetes, with or without obesity, in the hospital setting
Medical University of Vienna, Hospital de Cascais Dr. José de Almeida (Portugal), Centre Hospitalier Universitaire Sétif, Service Médecine Interne (Algeria), Rabin Medical Center, Hospital Regional de Malaga, Charles University, Czech Republic, University Hospital Bratislava, Complejo Hospitalario de Especialidades Juan Ramón Jimenez, Medical University Innsbruck, Aristotle University Of Thessaloniki, Rostov State Medical University, Hospital Marina Baixa, Riga East Clinical University Hospital, University Hospital, Aachen, San Raffaele University Hospital, Italy, Kanuni Sultan Suleyman Training and Research Hospital
Diabetes Mellitus, Obesity
11/24
01/25
Hominal, Miguel
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial

Hourglass Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity
Completed
3
731
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
07/24
07/24
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05565742: A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

Completed
2
320
Europe, Japan, US, RoW
LY3819469, Placebo
Eli Lilly and Company
Lipoprotein Disorder
10/23
10/24
PROLONG-ANG3, NCT05256654: A Study of LY3561774 in Participants With Mixed Dyslipidemia

Completed
2
205
Europe, Canada, Japan, US, RoW
LY3561774, Solbinsiran, Placebo
Eli Lilly and Company
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
03/24
05/24
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Terminated
2
335
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
STRONG-HF, NCT03412201 / 2018-000486-37: Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies

Recruiting
N/A
1800
Europe, RoW
Usual Care, High Intensity Care
Heart Initiative, Hôpitaux Universitaires Saint-Louis-Lariboisière, Momentum Research, Inc., Roche Diagnostics, Inserm UMRS 942
Heart Failure
10/21
10/21
LACROSS, NCT04456842: Cardiovascular Registry of Atrial Fibrillation

Completed
N/A
2016
RoW
Patient Registry Data
Brazilian Clinical Research Institute
Atrial Fibrillation, Atrial Flutter
09/24
09/24
Takacs, Eva Judit
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kautzky-Willer, Alexandra
Test2Func, NCT03851627: Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Recruiting
4
32
Europe
Testosterone Undecanoate, Nebido, Placebo, oily solution, Nebido like Placebo
Alexandra Kautzky-Willer, Bayer
Fatty Liver, Overweight/Obesity, Prediabetes/Type2 Diabetes Mellitus, Hypogonadism, Male
09/28
12/28
NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Recruiting
4
2400
Europe, RoW
RAS-antagonist and beta-blocker up-to maximal dosages, Enalapril 40mg/d, Ramipril 10mg/d, Lisinopril 40mg/d, Cilazapril 5mg/d, Perindopril 8mg/d, Captopril 150mg/d, Spirapril 24mg/d, Quinapril 40mg/d, Trandolapril 4mg/d, Zofenopril 60mg/d, Fosinopril 40mg/d, Candesartan 32mg/d, Valsartan 320mg/d, Irbesartan 300mg/d, Losartan 150mg/d, Eprosartan 800mg/d, Bisoprolol 10mg/d, Metoprololsuccinat 200mg/d, Carvedilol 50mg/d (100mg/d if weight is > 85kg), Nebivolol 10mg/d, RAS-antagonist and beta-blocker none or at stable dose
Martin Huelsmann
Heart Diseases, Diabetes Mellitus, Type 2
12/25
12/26
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT06245681: Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content

Recruiting
N/A
40
Europe
gender affirming hormone therapy
Medical University of Vienna
Gender Dysphoria
10/25
10/25
NCT06291675: Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content

Recruiting
N/A
50
Europe
gender-affirming hormone therapy
Medical University of Vienna
Gender Dysphoria, Hormone Therapy Induced Morphologic Change
03/26
03/33
DiabesityDay, NCT06680674: Multinational Point Prevalence Study on the Management of Diabesity in Hospitals

Not yet recruiting
N/A
400
NA
Routine care for people with diabetes, with or without obesity, in the hospital setting
Medical University of Vienna, Hospital de Cascais Dr. José de Almeida (Portugal), Centre Hospitalier Universitaire Sétif, Service Médecine Interne (Algeria), Rabin Medical Center, Hospital Regional de Malaga, Charles University, Czech Republic, University Hospital Bratislava, Complejo Hospitalario de Especialidades Juan Ramón Jimenez, Medical University Innsbruck, Aristotle University Of Thessaloniki, Rostov State Medical University, Hospital Marina Baixa, Riga East Clinical University Hospital, University Hospital, Aachen, San Raffaele University Hospital, Italy, Kanuni Sultan Suleyman Training and Research Hospital
Diabetes Mellitus, Obesity
11/24
01/25
Hominal, Miguel
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial

Hourglass Feb 2024 - Dec 2024 : Data from SUMMIT trial in participants with heart failure with preserved ejection fraction and obesity
Completed
3
731
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
07/24
07/24
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT05565742: A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

Completed
2
320
Europe, Japan, US, RoW
LY3819469, Placebo
Eli Lilly and Company
Lipoprotein Disorder
10/23
10/24
PROLONG-ANG3, NCT05256654: A Study of LY3561774 in Participants With Mixed Dyslipidemia

Completed
2
205
Europe, Canada, Japan, US, RoW
LY3561774, Solbinsiran, Placebo
Eli Lilly and Company
Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
03/24
05/24
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Terminated
2
335
Europe, Canada, Japan, US, RoW
LY3540378, Placebo
Eli Lilly and Company
Heart Failure, Heart Failure With Preserved Ejection Fraction
01/25
01/25
STRONG-HF, NCT03412201 / 2018-000486-37: Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP testinG, of Heart Failure Therapies

Recruiting
N/A
1800
Europe, RoW
Usual Care, High Intensity Care
Heart Initiative, Hôpitaux Universitaires Saint-Louis-Lariboisière, Momentum Research, Inc., Roche Diagnostics, Inserm UMRS 942
Heart Failure
10/21
10/21
LACROSS, NCT04456842: Cardiovascular Registry of Atrial Fibrillation

Completed
N/A
2016
RoW
Patient Registry Data
Brazilian Clinical Research Institute
Atrial Fibrillation, Atrial Flutter
09/24
09/24
Takacs, Eva Judit
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27

Download Options